CIGNA Pharmacy Management (CIGNA) has joined forces with The Leukemia & Lymphoma Society (LLS) to promote the LLS financial aid program for patients with multiple myeloma and other blood cancers.

The LLS program assists blood cancer patients and their families by helping cover the costs of private health insurance premiums, co-payment obligations, Medicare Part B and Part D, Medicare Supplementary Health Insurance, and Medicare Advantage premiums and co-payment obligations. The aid package provides up to $5,000…

The FDA last Friday granted approval to Cephalon, Inc. to market the drug Treanda (bendamustine) for the treatment of indolent non-Hodgkin’s lymphoma (NHL).

Just seven months ago, the FDA also approved Treanda for the treatment of chronic lymphocytic leukemia (CLL), making Treanda the only new drug this year to gain FDA approval for two cancer indications.

Treanda is not officially approved in the United States for the treatment of multiple myeloma. It is, however, approved…